NEW YORK--(BUSINESS WIRE)--June 7, 2006--Antigenics: Antigenics, Inc. (NASDAQ: AGEN - News) today announced that it has completed an in-depth analysis of its Phase 3 study of Oncophage® (vitespen) vaccine in kidney cancer. Review of the data at an international expert panel meeting on June 2, 2006, found that in the full analysis set* (FAS, which represents the true adjuvant patient population intended for the trial), there was a clinically significant improvement in recurrence-free survival (RFS) associated with Oncophage in a well defined subgroup of better-prognosis FAS patients.
